KR20230023727A - 나노지단백질-폴리펩티드 접합체 및 조성물, 시스템, 및 이의 사용 방법 - Google Patents

나노지단백질-폴리펩티드 접합체 및 조성물, 시스템, 및 이의 사용 방법 Download PDF

Info

Publication number
KR20230023727A
KR20230023727A KR1020237000866A KR20237000866A KR20230023727A KR 20230023727 A KR20230023727 A KR 20230023727A KR 1020237000866 A KR1020237000866 A KR 1020237000866A KR 20237000866 A KR20237000866 A KR 20237000866A KR 20230023727 A KR20230023727 A KR 20230023727A
Authority
KR
South Korea
Prior art keywords
antigen
conjugate
peptide
binding polypeptide
ckp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237000866A
Other languages
English (en)
Korean (ko)
Inventor
휘트니 빈더
크레이그 디. 블량셰
마틴 에이. 다르위시
라미 한노우시
신신 가오
Original Assignee
제넨테크, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 제넨테크, 인크. filed Critical 제넨테크, 인크.
Publication of KR20230023727A publication Critical patent/KR20230023727A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6917—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a lipoprotein vesicle, e.g. HDL or LDL proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Dispersion Chemistry (AREA)
  • Nanotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020237000866A 2020-06-11 2021-06-10 나노지단백질-폴리펩티드 접합체 및 조성물, 시스템, 및 이의 사용 방법 Pending KR20230023727A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063038075P 2020-06-11 2020-06-11
US63/038,075 2020-06-11
US202163151591P 2021-02-19 2021-02-19
US63/151,591 2021-02-19
PCT/US2021/036878 WO2021252803A1 (en) 2020-06-11 2021-06-10 Nanolipoprotein-polypeptide conjugates and compositions, systems, and methods using same

Publications (1)

Publication Number Publication Date
KR20230023727A true KR20230023727A (ko) 2023-02-17

Family

ID=76744974

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237000866A Pending KR20230023727A (ko) 2020-06-11 2021-06-10 나노지단백질-폴리펩티드 접합체 및 조성물, 시스템, 및 이의 사용 방법

Country Status (12)

Country Link
US (1) US20240059755A1 (https=)
EP (1) EP4164693A1 (https=)
JP (1) JP2023529203A (https=)
KR (1) KR20230023727A (https=)
CN (1) CN115803063A (https=)
AU (1) AU2021289738A1 (https=)
BR (1) BR112022025227A2 (https=)
CA (1) CA3183808A1 (https=)
IL (1) IL298878A (https=)
MX (1) MX2022015651A (https=)
TW (1) TW202214307A (https=)
WO (1) WO2021252803A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024258229A1 (ko) * 2023-06-15 2024-12-19 알엔에이진(주) 아포지질단백질 또는 이의 단편을 포함하는 융합 단백질 및 이의 용도

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2023269666A1 (en) * 2022-05-13 2024-11-28 Kisbee Therapeutics, Inc. Apoe lipoprotein systems
CN121293315A (zh) * 2025-09-26 2026-01-09 南开大学 纳米磷脂盘中bcma全长受体的构建方法及应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4975278A (en) 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
US5606040A (en) 1987-10-30 1997-02-25 American Cyanamid Company Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group
US5053394A (en) 1988-09-21 1991-10-01 American Cyanamid Company Targeted forms of methyltrithio antitumor agents
EP0368684B2 (en) 1988-11-11 2004-09-29 Medical Research Council Cloning immunoglobulin variable domain sequences.
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
CA2372813A1 (en) 1992-02-06 1993-08-19 L.L. Houston Biosynthetic binding protein for cancer marker
ZA932522B (en) 1992-04-10 1993-12-20 Res Dev Foundation Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens
DK0752248T3 (da) 1992-11-13 2000-11-13 Idec Pharma Corp Terapeutisk anvendelse af kimæriske og radioaktivt mærkede antistoffer mod humant B-lymfocytbegrænset differentieringsantig
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
EP2478912B1 (en) 2003-11-06 2016-08-31 Seattle Genetics, Inc. Auristatin conjugates with anti-HER2 or anti-CD22 antibodies and their use in therapy
WO2008141230A1 (en) 2007-05-09 2008-11-20 Lawrence Livermore National Security, Llc Methods and systems for monitoring production of a target protein in a nanolipoprotein particle
US8883729B2 (en) 2008-05-22 2014-11-11 Lawrence Livermore National Security, Llc Nanolipoprotein particles and related compositions, methods and systems
EP2890389A1 (en) 2012-08-28 2015-07-08 Novartis AG Use of a vegf antagonist in treating ocular vascular proliferative diseases
WO2017035326A1 (en) 2015-08-25 2017-03-02 Lawrence Livermore National Security, Llc Stable nanolipoprotein particles and related compositions methods and systems
TWI799366B (zh) 2015-09-15 2023-04-21 美商建南德克公司 胱胺酸結骨架平臺
WO2017155837A1 (en) 2016-03-07 2017-09-14 Lawrence Livermore National Security, Llc Nanolipoprotein particles and related compositions methods and systems for improved drug loading
US12083223B2 (en) 2017-05-02 2024-09-10 Lawrence Livermore National Security, Llc Nanolipoprotein particles and related compositions methods and systems for loading RNA
US11491215B2 (en) * 2018-05-24 2022-11-08 Lawrence Livermore National Security, Llc Antigenic combinations against Francisella bacteria and related nanolipoprotein particles, compositions, methods and systems

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024258229A1 (ko) * 2023-06-15 2024-12-19 알엔에이진(주) 아포지질단백질 또는 이의 단편을 포함하는 융합 단백질 및 이의 용도

Also Published As

Publication number Publication date
JP2023529203A (ja) 2023-07-07
BR112022025227A2 (pt) 2023-01-03
AU2021289738A1 (en) 2022-12-15
MX2022015651A (es) 2023-01-16
CA3183808A1 (en) 2021-12-16
WO2021252803A1 (en) 2021-12-16
TW202214307A (zh) 2022-04-16
CN115803063A (zh) 2023-03-14
IL298878A (en) 2023-02-01
US20240059755A1 (en) 2024-02-22
EP4164693A1 (en) 2023-04-19

Similar Documents

Publication Publication Date Title
US20240059755A1 (en) Nanolipoprotein-polypeptide conjugates and compositions, systems, and methods using same
Dimasi et al. The design and characterization of oligospecific antibodies for simultaneous targeting of multiple disease mediators
EP2550297B1 (en) Disulfide stabilized dvd-lg molecules
JP6413127B2 (ja) 変異抗体およびそのコンジュゲーション
US20210379153A1 (en) Combination therapies comprising sirp alpha-based chimeric proteins
JP2022553830A (ja) Ｎ末端ｓｃＦｖ多重特異性結合分子
US20200071380A1 (en) Combination therapies comprising sirp alpha-based chimeric proteins
JP2020519696A (ja) 多重特異性タンパク質薬物およびそのライブラリー、ならびに製造方法と使用
US20210324041A1 (en) Combination therapies
US20240141014A1 (en) Mutant pd-1 extracellular domains
WO2023086929A1 (en) Sirp1a - and cd40l-based chimeric proteins
JP2024543158A (ja) 多重特異性リガンド結合分子及びその用途
JP2023524866A (ja) 抗ｉｌ－３３抗体の処方物
HK40089788A (zh) 纳米脂蛋白-多肽缀合物和组合物、系统以及其使用方法
US20210179689A1 (en) Combination therapies comprising tim-3-based chimeric proteins
JP2023524444A (ja) 医薬製剤
WO2024026340A1 (en) Combination therapy for treatment of ovarian cancer
HK40092774A (zh) 使用激活素受体ii型变体的方法

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902